People with episodic migraine often struggle to find relief. A large analysis of data looked at seven different treatments to see which ones truly work. The group included 24,418 participants with a mean age of 39.2 years. Most were women, and their average migraine count before treatment was 8.2 days per month. The study compared new drugs against a placebo to measure real benefits.
The results showed clear improvements for everyone who took the new medications. One injectable drug reduced monthly migraine days by an average of 2.40 days compared to placebo. Another injectable had a high ranking for overall benefit. A third injectable also performed significantly better than the placebo group. These drugs belong to a class that targets specific proteins involved in migraine pain.
When comparing the two main types of drugs, the injectables showed slightly better results than the oral pills. The injectables reduced monthly migraine days by about 1.1 more days on average than the pills. However, the oral pills were very safe and worked similarly well to a placebo in terms of side effects. The study authors recommend choosing a treatment based on personal needs like how you prefer to take medicine and your other health conditions.